-- 信实工业周五公布了第四季度财报,总吞吐量从去年同期的2030万吨降至1950万吨。 该公司表示,截至3月31日的季度,用于运输燃料的产量降至1110万吨,而去年同期为1200万吨。 第四季度,克里希纳-戈达瓦里-迪鲁拜6号气田的天然气产量同比下降6.4%,至596亿立方英尺当量。 该公司表示,煤层气产量增长7.4%,达到29.1亿立方英尺当量,这得益于新增投产井的贡献。 信实工业表示,尽管传统气田产量下降,但克里希纳-戈达瓦里-迪鲁拜6号气田的天然气日均产量为2520万标准立方米,煤层气日均产量为92万标准立方米,表明公司运营表现稳定。 该公司表示,本季度石油和凝析油日均产量为17,310桶。 该公司表示,将继续专注于通过改进油井干预措施、提高采收率技术以及在其上游业务组合中逐步开发来稳定产量。 该公司表示,信实工业正在扩大其太阳能制造产能,目标是在组件、电池、硅片和玻璃制造方面实现20吉瓦的年产量,并已获得异质结技术太阳能电池和组件的制造商认可清单(ALM)。 该公司补充说,该公司还在扩大电池制造规模,目标是达到100吉瓦时的年产能,其中40吉瓦时的第一阶段预计很快投产。 据该公司称,信实正在推进位于库奇的大型可再生能源项目,目标是超过150吉瓦的峰值装机容量,该项目建设与输电基础设施建设同步进行。 该公司还表示,已与三星物产达成一项长期协议,从 2029 年开始供应绿色氨,以支持其构建综合清洁能源和燃料平台的战略。
Related Articles
Fadu Returns to Profit in Q1 as Sales Triple; Shares Jump 14%
Fadu (KOSDAQ:440110) posted first-quarter net income of 10.2 billion won, rebounding from a net loss of 12.1 billion won a year earlier, according to a Monday filing with the Korea Exchange.The South Korean chipmaker's sales revenue surged 210% year over year to 59.5 billion won from 19.2 billion won.Shares of Fadu jumped nearly 14% in recent trade.
ASX Biggest Losers
Here are the 10 ASX-listed companies with the biggest losses on Monday.Wisetech (ASX:WTC): -3%, AU$42.79NexGen Energy (ASX:NXG): -3%, AU$17.26Telix Pharmaceuticals (ASX:TLX): -2%, AU$14.47Cochlear (ASX:COH): -2%, AU$94.76Paladin Energy (ASX:PDN): -2%, AU$12.28Origin Energy (ASX:ORG): -2%, AU$12.44EVT (ASX:EVT): -2%, AU$12.44Tuas (ASX:TUA): -2%, AU$5.97Ramsay Health Care (ASX:RHC): -2%, AU$39.15Southern Cross Gold (ASX:SX2): -2%, AU$11.07
Sun Pharmaceutical to Acquire US-Based Organon in $11.8 Billion Deal
Sun Pharmaceutical Industries (NSE:SUNPHARMA, BOM:524715) has agreed to acquire US-based Organon & Co in an all-cash deal at an enterprise valuation of $11.8 billion, according to a Monday filing to the Indian stock exchanges.Under the pact, Sun Pharmaceutical will buy all outstanding shares of Organon for $14.00 per share. It plans to fund the acquisition through a combination of available cash resources and committed financing from banks.The acquisition is estimated to boost Sun Pharmaceutical's revenues to $12.4 billion.Organon, which was spun off from Merck in 2021, specializes in women's health and biosimilars and has more than 70 products sold across 140 countries.The Organon buyout is part of Sun Pharmaceutical's strategy "of growing its Innovative Medicines business," according to Sun Pharma's statement.The transaction is subject to customary closing conditions, including receipt of required regulatory approvals andapproval by Organon stockholders.